MediWound Ltd.
Close on Oct 19, 2026
- Market cap
- $167.72M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $3.10M | $-0.57 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $1.90M | $-0.56 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $5.70M | $-1.23 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 19, 2025 | Before market open | $5.80M | $-0.36 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | $5.10M | $-0.68 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 21, 2024 | Before market open | $5.30M | $-0.19 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 15, 2023 | During market hours | $4.80M | $0.10 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 16, 2023 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 9, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 17, 2022 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| revenue guidance | full-year 2026 | $24.00M to $26.00M | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements MediWound filed with the SEC
Second Quarter 2026 Financial Results and Provides Corporate Update
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
42 Hayarkon Street, Yavne 8122745, Israel
EX-99.1 to Form 6-K
PROXY FOR THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
MediWound Reports Fourth Quarter and Full Year 2025 Financial Results
EX-99.1 to Form 6-K
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
PROXY FOR THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
NOTICE OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
PROXY FOR THE 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
TO BE HELD ON DECEMBER 19, 2024
EX-99.2 to Form 6-K
MediWound Announces U.S. Food and Drug Administration Approval of
EX-99.1 to Form 6-K
Represents an amount lower than $1.
EX-99.2 to Form 6-K
Operating and Financial Review and Prospects
EX-99.3 to Form 6-K
MediWound Announces Positive Results from the U.S. NexoBrid ®
EX-99 to Form 6-K
MediWound Announces €16.25 Million Funding from the European
EX-99.1 to Form 6-K
MediWound Announces $25 Million Strategic Private Placement Financing
EX-99.1 to Form 6-K
NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
PROXY FOR THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
Positive Results in Head-to-Head Comparison of EscharEx ® vs.
EX-99.1 to Form 6-K
February 2024 I Nasdaq: MDWD Next-Generation Enzymatic Therapeuticsfor
EX-99.2 to Form 6-K
MediWound Announces that FDA has Accepted for Review the Supplement to the
EX-99.1 to Form 6-K
January 2024 I Nasdaq: MDWD Next-Generation Enzymatic Therapeuticsfor
EX-99.1 to Form 6-K
MediWound Secures Additional U.S. Department of Defense Funding to
EX-99.1 to Form 6-K